Expression of Tenascin-C in Various Human Brain Tumors and its Relevance for Survival in Patients with Astrocytoma

Cancer

Volumn 98, Issue 11, 2003, Pages 2430-2439

  Leins, Alexander ^a,b   Riva, Pietro ^c   Lindstedt, Ragnar ^d   Davidoff, Michail S ^b   Mehraein, Parviz ^a   Weis, Serge ^a,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c BUFALINI HOSPITAL   (Italy)

^d Sigma Tau SpA   (Italy)

^e Stanley Medical Research Institute   (United States)

Author keywords

Central nervous system tumors; Extracellular matrix (ECM); Glioblastoma multiforme (GBM); Tenascin C (TN C)

Indexed keywords

TENASCIN;

ARTICLE; ASTROCYTOMA; BRAIN REGION; BRAIN TUMOR; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EXTRACELLULAR MATRIX; FRONTAL LOBE; GLIOBLASTOMA; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; MENINGIOMA; METASTASIS; NEURILEMOMA; OCCIPITAL LOBE; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL TIME; TEMPORAL LOBE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ASTROCYTOMA; AUTOPSY; BLOTTING, WESTERN; BRAIN CHEMISTRY; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TENASCIN;

EID: 0344412950     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11796     Document Type: Article

References (44)

1. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983;43:2796-2805.
2. Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol. 1989;5:71-92.
3. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn. 2000;218:235-259.
4. Carnemolla B, Castellani P, Ponassi M, et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol. 1999;154:1345-1352.
5. Dorries U, Schachner M. Tenascin mRNA isoforms in the developing mouse brain. J Neurosci Res. 1994;37:336-347.
6. Tucker RP, Spring J, Baumgartner S, et al. Novel tenascin variants with a distinctive pattern of expression in the avian embryo. Development. 1994;120:637-647.
7. Goldbrunner RH, Bernstein JJ, Tonn JC. Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir (Wien). 1999;141:295-305.
8. Castellani P, Dorcaratto A, Siri A, Zardi L, Viale GL. Tenascin distribution in human brain tumours. Acta Neurochir (Wien). 1995;136:44-50.
9. Friedlander DR, Zagzag D, Shiff B, et al. Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and betal integrins. Cancer Res. 1996;56:1939-1947.
10. Hasegawa K, Yoshida T, Matsumoto K, Katsuta K, Waga S, Sakakura T. Differential expression of tenascin-C and tenascin-X in human astrocytomas. Acta Neuropathol (Berlin). 1997;93:431-437.
11. Hasegawa T, Seki K, Yang P, et al. Differentiation and proliferative activity in benign and malignant cartilage tumors of bone. Hum Pathol. 1995;26:838-845.
12. Jallo GI, Friedlander DR, Kelly PJ, Wisoff JH, Grumet M, Zagzag D. Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis. Neurosurgery. 1997;41:1052-1059.
13. Natali PG, Nicotra MR, Bigotti A, et al. Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer. 1991;47:811-816.
14. Zagzag D, Friedlander DR, Miller DC, et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res. 1995;55:907-914.
15. Riva P, Franceschi G, Frattarelli M, et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a Phase I study. Clin Cancer Res. 1999;5:3275s-3280s.
16. Arista A, Sturiale C, Riva P, et al. Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas. Acta Neurochir (Wien). 1995;135:159-162.
17. Riva P, Arista A, Tison V, et al. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer. 1994;73:1076-1082.
18. Riva P, Arista A, Sturiale C, et al. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2. Int J Cancer. 1992;51:7-13.
19. Riva P, Arista A, Franceschi G, et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. 1995;55:5952s-5956s.
20. Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol. 1998;16:2202-2212.
21. Merlo A, Jermann E, Hausmann O, et al. Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas. Int J Cancer. 1997;71:810-816.
22. Paganelli G, Bartolomei M, Ferrari M, et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother Radiopharm. 2001;16:227-235.
23. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81 C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000;18:3862-3872.
24. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389-1397.
25. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3:255-268.
26. Kleihues Pm Cavanee WK. Pathology and genetics of tumours of the nervous system. World Health Organization classification of tumours. Lyon: IARC Press, 2000.
27. Burger PC, Scheithauer BW. Tumors of the nervous system. Atlas of tumor pathology. Third series, fascicle 10. Washington, DC: Armed Forces Institute of Pathology, 1994.
28. Balza E, Siri A, Ponassi M, et al. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett. 1993;332:39-43.
29. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD. Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol. 1992;36:41-55.
30. Perides G, Erickson HP, Rahemtulla F, Bignami A. Colocalization of tenascin with versican, a hyaluronate-binding chondroitin sulfate proteoglycan. Anat Embryol (Berl). 1993;188:467-479.
31. Tews DS, Nissen A. Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Invasion Metastasis. 1998;18:271-284.
32. Enam SA, Rosenblum ML, Edvardsen K. Role of extracellular matrix in tumor invasion: migration of glioma cells along fibronectin-positive mesenchymal cell processes. Neurosurgery. 1998;42:599-607.
33. Brodkey JA, Laywell ED, O'Brien TF, et al. Focal brain injury and upregulation of a developmentally regulated extracellular matrix protein. J Neurosurg. 1995;82:106-112.
34. Laywell ED, Dorries U, Bartsch U, Faissner A, Schachner M, Steindler DA. Enhanced expression of the developmentally regulated extracellular matrix molecule tenascin following adult brain injury. Proc Natl Acad Sci USA. 1992;89:2634-268.
35. Zagzag D, Friedlander DR, Dosik J, et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res. 1996;56:182-189.
36. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest. 2001;107:785-790.
37. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of Tenascin-C expression during glioma progression. Int J Cancer. 2002;98:362-369.
38. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995;55:1856-1862.
39. Giese A, Loo MA, Rief MD, Tran N, Berens ME. Substrates for astrocytoma invasion. Neurosurgery. 1995;37:294-301
40. Sriramarao P, Mendler M, Bourdon MA. Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J Cell Sci. 1993;105(Pt 4):1001-12.
41. Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, Virtanen I. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol. 1991;22:636-643.
42. Smith GM, Hale JH. Macrophage/microglia regulation of astrocytic tenascin: synergistic action of transforming growth factor-beta and basic fibroblast growth factor. J Neurosci. 1997;17:9624-9633.
43. Tucker RP, Hammarback JA, Jenrath DA, Mackie EJ, Xu Y. Tenascin expression in the mouse: in situ localization and induction in vitro by bFGF. J Cell Sci. 1993;104:69-76.
44. Zagzag D, Shiff B, Jallo GI, et al. Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Research. 2002;62:2660-2668.